CAMP
CAMP4 Therapeutics Corp (CAMP)
Healthcare • NASDAQ • $4.46+2.76%
- Symbol
- CAMP
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $4.46
- Daily Change
- +2.76%
- Market Cap
- $231.59M
- Trailing P/E
- N/A
- Forward P/E
- -5.85
- 52W High
- $7.75
- 52W Low
- $1.31
- Analyst Target
- $8.20
- Dividend Yield
- N/A
- Beta
- N/A
Camp4 Therapeutics Corporation, a clinical-stage biopharmaceutical company, discovers and develops RNA-based therapeutics to treat a range of genetic diseases. Its lead product candidate is CMP-001, which is in a Phase 1/2 clinical trial for the treatment of urea cycle disorders. The company also develops CMP-002 for the treatment of SYNGAP1-related disorders. Camp4 Therapeutics Corporation was formerly known as Marauder Therapeutics, Inc. and changed its name to Camp4 Therapeutics Corporation in March 2018. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Company websiteResearch CAMP on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.